Roivant Sciences Ltd. Common Shares
Veridion Score
Composite trend over time
Why is ROIV moving today?
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ROIV.
ROIV insider activity
Roivant Sciences Ltd. Common Shares
No multi-insider buying cluster in the last 90 days
Net selling: -$584.4M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-26 | 2026-06-24 | Venker Eric | Insider | sell | $33.51 | 46,234 | 1,613,063 | $1.5M | SEC Form 4 |
| 2026-06-26 | 2026-06-24 | Venker Eric | Insider | sell | $33.05 | 153,766 | 1,659,297 | $5.1M | SEC Form 4 |
| 2026-06-26 | 2026-06-24 | Venker Eric | Insider | buy | $3.85 | 200,000 | 1,813,063 | $770K | SEC Form 4 |
| 2026-06-23 | 2026-06-20 | Pulik Richard | Insider | sell | $31.43 | 2,129 | 276,420 | $67K | SEC Form 4 |
| 2026-06-23 | 2026-06-20 | Humes Jennifer | Insider | sell | $31.43 | 3,582 | 109,782 | $113K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 146 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moROIV contract awards, year to date.
Public federal awards linked to this ticker.
ROIV lobbying filings, year to date.
Registered lobbying filings matched to Roivant Sciences Ltd. Common Shares.